People: Emisphere Technologies, Inc. (EMIS.OB)
EMIS.OB on OTC BB
1.06USD
9 Feb 2010
1.06USD
9 Feb 2010
Price Change (% chg)
$0.06 (+6.00%)
$0.06 (+6.00%)
Prev Close
$1.06
$1.06
Open
--
--
Day's High
$1.06
$1.06
Day's Low
$0.95
$0.95
Volume
26,300
26,300
Avg. Vol
84,483
84,483
52-wk High
$1.49
$1.49
52-wk Low
$0.42
$0.42
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Novinski, Michael | 52 | 2008 | President, Chief Executive Officer, Director |
| Garone, Michael | 50 | 2008 | Chief Financial Officer, Vice President, Corporate Secretary |
| Riley, M. Gary | 66 | 2007 | Vice President - Non-clinical Development and Applied Biology |
| Weiser, Michael | 46 | 2005 | Director |
| Rachesky, Mark | 50 | 2005 | Director |
| Harkey, John | 48 | 2006 | Director |
| Rothwell, Timothy | 51 | 2009 | Director |
Biographies
| Name | Description |
|---|---|
| Novinski, Michael | Mr. Michael V. Novinski is President, Chief Executive Officer, Director of Emisphere Technologies Inc. He joined Emisphere in 2007 as President and Chief Executive Officer. Mr. Novinski has been a Director of the Company since 2008. Immediately before joining the Company, Mr. Novinski was President and a member of the Board of Directors of Organon USA Inc., a business unit of Organon BioSciences Inc. Mr. Novinski served as Organon’s Director of Marketing beginning in 1992 and held several senior executive positions within Organon BioSciences prior to becoming President of Organon USA in 2003. Mr. Novinski earned a Bachelor’s degree with a major in Biology from Washington and Jefferson College in Washington, PA. He also studied under fellowship at the University of Pittsburgh Medical School, Department of Microbiology. |
| Garone, Michael | Mr. Michael R. Garone serves as Chief Financial Officer, Vice President, Corporate Secretary of Emisphere Technologies Inc. He joined Emisphere in 2007 as Vice President and Chief Financial Officer. Mr. Garone has also served as the Company’s Corporate Secretary since October 2008. Mr. Garone previously served as Interim Chief Executive Officer and Chief Financial Officer of Astralis, Ltd. (OTC BB: ASTR.OB) Mr. Garone spent 20 years at AT&T (NYSE: T), where he held several positions, including Chief Financial Officer of AT&T Alascom. Mr. Garone received a MBA from Columbia University and a BA in Mathematics from Colgate University, Hamilton, NY. |
| Riley, M. Gary | Mr. M. Gary I. Riley joined Emisphere Technologies, Inc. in November 2007 as Vice-President of Nonclinical Development and Applied Biology. He was previously Vice President of Toxicology and Applied Biology at Alkermes, Inc., Cambridge, MA, where he spent 14 years working in the field of specialized drug delivery systems. He holds board certifications in veterinary pathology and toxicology. He was previously employed as Director of Pathobiology at Lederle Laboratories and earlier in his career held positions as a veterinary pathologist in academia and industry. |
| Weiser, Michael | Dr. Michael Weiser has been a Director of Emisphere Technologies, Inc. since 2005. Dr. Weiser is the founder and co-chairman at Actin Biomed, a healthcare investment firm. Before joining Actin, Dr. Weiser was the Director of Research of Paramount BioCapital, Inc. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine, where he also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience. Dr. Weiser serves on the boards of Manhattan Pharmaceuticals, Inc. (OTCBB: MHA), Hana Biosciences, Inc. (AMEX: HNAB), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Ziopharm Oncology, Inc. (NASDAQ: ZIOP), VioQuest Pharmaceuticals, Inc. (OTCBB: VQPH) and several privately-held biotechnology companies. |
| Rachesky, Mark | Dr. Mark H. Rachesky has been a Director of Emisphere Technologies, Inc. since 2005. Dr. Rachesky is the co-founder and President of MHR Fund Management LLC and affiliates, investment managers of various private investment funds that invest in inefficient market sectors, including special situation equities and distressed investments. From 1990 through June 1996, Dr. Rachesky was employed by Carl C. Icahn, initially as a senior investment officer and for the last three years as sole Managing Director of Icahn Holding Corporation, and acting chief investment advisor. Dr. Rachesky is currently the Non-Executive Chairman of the Board of Loral Space & Communications, Inc. (NASDAQ: LORL), Telesat Canada and Leap Wireless International, Inc. (NASDAQ: LEAP) and is a member of the Board of Directors of Nations Health, Inc. (NASDAQ: NHRX). Dr. Rachesky is a graduate of Stanford University School of Medicine and Stanford University School of Business. Dr. Rachesky graduated from the University of Pennsylvania with a major in Molecular Aspects of Cancer. |
| Harkey, John | Mr. John D. Harkey, Jr. has been a Director Emisphere Technologies, Inc. since April 2006. Mr. Harkey is Chairman and Chief Executive Officer of Consolidated Restaurant Companies, Inc., which owns, operates and franchises full-service restaurants in the U.S., the Middle East and the United Kingdom. Mr. Harkey also serves on the Board of Directors of Leap Wireless International, Inc. (NASDAQ:LEAP), Energy Transfer companies (NYSE:ETE and ETP), Loral Space & Communications, Inc. (NASDAQ:LORL) and the Baylor Health Care System Foundation. Mr. Harkey also serves on the Executive Board of Circle Ten Council of the Boy Scouts of America and is a member of the Young President’s Organization. Mr. Harkey obtained a B.B.A. from the Business Honors Program at the University of Texas at Austin. He earned an M.B.A from Stanford University School of Business and a J.D. from the University of Texas School of Law. |
| Rothwell, Timothy | Mr. Timothy Rothwell is Director of Emisphere Technologies, Inc. From February 2007 to March 2009, Mr. Rothwell served as Chairman of Sanofi-aventis U.S. From September 2004 to February 2007, Mr. Rothwell was President and Chief Executive Officer of the company, overseeing all domestic commercial operations as well as coordination of Industrial Affairs and Research and Development activities.From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-aventis U.S. in 2004. Prior to that, from June 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company's Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company's Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President, Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation. Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his Juris Doctor from Seton Hall University. Presently, he serves on the PhRMA Board of Directors, as well as the Institute of Medicine's Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswomen's Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey and the Board of Visitors for Seton Hall Law School. Mr. Rothwell also serves as a Trustee of the Corporate Council for America's Children at the Children's Health Fund. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Novinski, Michael | 1,673,360 |
| Garone, Michael | 283,442 |
| Riley, M. Gary | 406,825 |
| Weiser, Michael | -- |
| Rachesky, Mark | -- |
| Harkey, John | -- |
| Rothwell, Timothy | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Novinski, Michael | 0 | 0 |
| Garone, Michael | 0 | 0 |
| Riley, M. Gary | 0 | 0 |
| Weiser, Michael | 0 | 0 |
| Rachesky, Mark | 0 | 0 |
| Harkey, John | 0 | 0 |
| Rothwell, Timothy | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| RILEY GARY | 7,500 | $0.74 |
| RILEY GARY | 5,000 | $0.71 |
| RILEY GARY | 7,000 | $0.70 |
| RILEY GARY | 5,000 | $0.72 |
| RILEY GARY | 5,000 | $0.70 |
| RACHESKY MARK H | 1,207,538 | $0.00 |
| RACHESKY MARK H | 3,323,900 | $0.00 |
| RACHESKY MARK H | 1,319,372 | $0.00 |
| RACHESKY MARK H | 164,227 | $0.00 |
| RILEY GARY | 200 | $4.08 |
| RILEY GARY | 6,000 | $4.15 |
| RILEY GARY | 200 | $4.19 |
| RILEY GARY | 400 | $4.10 |
| RILEY GARY | 737 | $4.17 |
| RILEY GARY | 300 | $4.07 |
| RILEY GARY | 4,400 | $4.14 |
| RILEY GARY | 300 | $4.13 |
| RILEY GARY | 100 | $4.19 |
| RILEY GARY | 319 | $4.09 |
| RILEY GARY | 500 | $4.16 |
| RILEY GARY | 14,744 | $4.20 |
| RILEY GARY | 1,600 | $4.06 |
| RILEY GARY | 100 | $4.11 |
| RILEY GARY | 100 | $4.18 |
| RILEY GARY | 1,100 | $4.18 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
